Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.
Erythropoietin is a growth factor commonly used to manage anemia in patients with chronic kidney disease. A significant clinical challenge is relative resistance to erythropoietin, which leads to use of successively higher erythropoietin doses, failure to achieve target hemoglobin levels, and increa...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-02-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC2821920?pdf=render |